EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

The full case · company in formation

EUTECNIQ in depth. The problem, the method and the evidence.

Botanical ingredients, engineered from molecule to manufacturing.

Schematic from plant to manufacturing: plant, molecule, extract, specify, scale.

EUTECNIQ is building the Large Botanical Model, a physics-informed scientific AI platform for botanical ingredients. Its first application is regulatory and development intelligence, including new dietary ingredient work; owned ingredients and licenses follow once the platform is validated.

The Ingredient Engine · from plant to specified ingredient

  1. 0IntakeScreen record
  2. 1DiscoverCandidate dossier, draft target profile
  3. 2SourceIdentity passport, supplier file
  4. 3ExtractProcess description, mass balance
  5. 4SpecifySpecification, validated methods
  6. 5DeliverPrototype, delivery dossier
  7. 6SafetySafety and exposure assessment
  8. 7ScaleTransfer package, control strategy
  9. 8MarketClient program, license, supply or partnered drug program

Schematic Each stage produces a record and ends in a go, change or stop decision. Select a stage to open it below.

Completed Computational studies of published data. Proposed Laboratories, trained models and services; none is operating. What exists today

Free tool · Everything I Take

Are your supplements adding up to too much?

Many people take a multivitamin and a few single supplements. The same vitamin can hide in several of them.

  • Vitamin D: a multivitamin with 1,000 IU plus a 5,000 IU softgel is 6,000 IU a day, above the 4,000 IU upper limit for adults.
  • Read a Supplement Facts panel, find a product in the NIH label database, or add foods.
  • See every total in one set of units, against U.S. and EU upper limits for your life stage.

Free, no account, stored only in your browser. A calculator, not medical advice; it does not check medicines.

Schematic, Everything I Take, in three steps: Add what you take Read a label, find a product or type an ingredient Units converted IU, folate, vitamin A forms, mineral salts Totals against upper limits U.S. and EU values for your life stage Free. No account. Your list stays in your browser. A calculator, not medical advice.

EUTECNIQ Atlas · evidence

How much research stands behind each compound?

Each point is one of 130 vitamins, minerals, fatty acids, amino acids, carotenoids and plant compounds, placed by how many randomized trials and how many PubMed records carry its name in the title. Point at a compound to read its counts; select it to open its record.

Research volume is not proof of an effect. The compound explorer grades what the trials found.

Open the compound explorer

130 compounds by research volumeScatter plot. Each point is one compound in EUTECNIQ Atlas, placed by the number of randomized controlled trials and the number of all PubMed records with the compound in the title, both on log scales, and colored by class. The full table is in the compound explorer.

Source: PubMed, U.S. National Library of Medicine, E-utilities; counts retrieved November 11, 2026. Title-word searches count publications, not quality or effect.

  • 130compounds in Atlas
  • 355graded findings
  • 136interactive calculators
  • 60research figures with data and code

New here? · In plain English

What EUTECNIQ does, without the jargon

Plant ingredients are hard to check. The label may not match what is inside, two batches can differ, mixing with other supplements, medicines or alcohol can change what they do, and many label claims rest on thin evidence. EUTECNIQ is being built to check all four in one place.

Schematic, Four problems a shopper cannot see: The label may not match 20.0% of 2,235 turmeric samples in published surveys were adulterated Batches differ One ginkgo marker varied 5.8-fold across 51 batches Mixing changes effects St. John’s wort cut a medicine’s exposure by 79.4% Claims need evidence A new ingredient needs a safety notification 75 days before sale Each number is from a published source cited on this page.

The case in 60 seconds

U.S. supplement makers must verify the identity of every dietary ingredient, and FDA cited specifications and their tests 711 times in FY2025. The first customer is a brand, ingredient supplier or importer with one botanical it cannot yet qualify, formulate or scale with confidence.

The problem

One connected workflow from molecule to manufacturing. Computed on published data: once the predicted solubility limit is applied, the curcumin extraction window shrinks from 100% to 34% of a 5–45 °C, 30–100% ethanol grid. That 34% is a model scenario with assumed extraction kinetics, not a verified operating window.

The demonstration

Paid programs come first. Where contracts allow, they leave methods the company keeps; owned ingredients, licensed processes and supply come later, each through its own gate, and are not revenue today.

The focus

A Ph.D. on the optimization-based design of ionic liquids, six granted patents from three families at prior employers, industrial experience since 2007. Capital would be released in stages against four checkpoints in 18 months.

The business model

01The problem

A botanical is bought by its name. What it is, what it contains and what reaches the body are seldom verified.

Supplement makers must confirm what every ingredient is before they use it. FDA’s own inspection records show how often that step fails.

The verification gap

1,938 FDA citations under the supplement manufacturing rule in FY2025, the most of any year since FY2014. 711 cite the specifications or the tests that verify them.

FDA Form 483 citations under 21 CFR Part 111: FY2022 1,218, of which 400 cite specifications or the tests that verify them; FY2023 1,173, of which 351 cite specifications or the tests that verify them; FY2024 1,583, of which 539 cite specifications or the tests that verify them; FY2025 1,938, of which 711 cite specifications or the tests that verify them.05001,0001,5002,0001,218400FY20221,173351FY20231,583539FY20241,938711FY2025
  • All citations under 21 CFR Part 111
  • Specifications (111.70) and the tests that verify them (111.75)

3×

Citations of the dietary-ingredient identity test, FY2022 to FY2025: 22, 15, 39, 66.

Citations of the dietary-ingredient identity test: FY2022 22, FY2023 15, FY2024 39, FY2025 66.222022152023392024662025
Published evidence U.S. FDA Inspection Observations, FY2022–FY2025, Foods tab, counted October 2026. Counts are citations, not rates; part of the rise since FY2021 reflects resumed inspections. The data and its limits

Three published measurements, one for each thing a buyer cannot see on the label

  1. 1Identity

    20.0%

    of 2,235 turmeric samples in 48 published surveys were adulterated (pooled, not market-wide).

    20.0% of 2,235 turmeric samples were adulterated: 20 of 100 cells.

    A content assay can miss it: HPLC could not separate 6 synthetic curcumin samples from 21 natural ones; a hydrogen isotope ratio separated all of them.

    Gafner et al., Pharm Biol 2026; Perini et al., Antioxidants 2023.

  2. 2Consistency

    5.8×

    range in one flavonol glycoside, rutin, across 51 batches of ginkgo tablets and capsules from 25 manufacturers.

    Rutin in 51 ginkgo batches ranged from 0.50 to 2.91 mg per 40 mg extract, a 5.8-fold range.01230.502.91rutin, mg per 40 mg extract

    A trial of one product does not carry over to another sold under the same name; a Cochrane review of St. John’s wort limited its conclusions to the extracts tested.

    Liu et al., Chin Med 2022; Linde et al., Cochrane 2008. Apply a specification to the 51 batches

  3. 3Exposure

    6.9–185×

    the exposure of unformulated curcumin, across ten formulations of the same compound.

    Ten curcumin formulations reached 6.9 to 185 times the exposure of unformulated curcumin: Schiborr 2014, micellar 185; Jäger 2014 136.3; Gota 2010 100; Purpura 2018 85; Cuomo 2011 48; Sasaki 2011 15.9; Im 2012 15.8; Madhavi and Kagan 2014 9.7; Schiborr 2014, micronized 9; Antony 2008 6.9. Studies differ in dose and design.1×10×100×6.9×185×exposure vs unformulated curcumin (log scale)

    Of 171 systematic reviews of oral curcumin, 3.5% reported bioavailability analyses in their methods. Higher plasma exposure is not evidence of a health effect.

    UK COT TOX/2025/09, Table 5; Bučević Popović et al., Pharmaceuticals 2024.

Each failure has an owner: the company whose name is on the label or the specification, which carries the rejected lot, the inconsistent product, the strengthened filing and the process that changes at scale. That function, in quality, product development or regulatory affairs, is the first buyer. Six documented failure modes

02The focus

EUTECNIQ’s focus: turn a botanical into an ingredient a buyer can specify, verify and license.

What is checkedCommodity extract, as usually tradedSpecified ingredient, as EUTECNIQ proposes
IdentityThe supplier’s certificate, relied on before it is confirmedVerified on every lot by orthogonal methods; natural origin by isotope ratio where a synthetic can copy the profile
CompositionSold by a marker percentageEach active and contaminant specified, with a reason for every limit and methods validated under ICH Q2(R2)
ExposureInferred from total contentA delivery form with its own exposure and safety data, reporting the parent compound and its conjugates separately
ProcessChanges can go unrecorded between lots and sitesA process with its ranges and control strategy, transferable to another site and licensable
Decision recordScattered across supplier, laboratory and manufacturerOne record from source to scale, with a go, change or stop decision at each of eight gates

Two horizons: what earns first, and what could be owned later

Proposed Horizon 1 · near-term commercial entry

Paid programs establish demand

  • A paid serviceSupplier qualification and comparability (Package B): whether clients pay for a faster, better-founded accept-or-reject decision on a botanical source.
  • Two further packagesIngredient feasibility and delivery selection (A); process optimization and technology transfer (C). Each ends in a go, change or stop recommendation.

Paid as project fees, development fees, transfer milestones

First test day 90: deposit-paid statements of work and a measured margin; letters of intent do not count

Repeatable methods

Methods and decision rules reused on the next client’s source of the same botanical, where contracts allow.

Gate day 365: at least one reusable method the company may keep. Month 18: an owned process or formulation candidate with counsel-reviewed ownership.

Proposed Horizon 2 · long-term potential

Owned ingredients and technology create scale

  • An owned ingredientThe flagship case: a turmeric extract with natural origin verified on every lot and a delivery form backed by its own exposure and safety data.
  • Delivery technologies and processesValidated where the evidence supports them, licensed to ingredient manufacturers for royalties.

Paid as supply margins per kilogram, licenses and royalties: revenue that does not need a new statement of work

Not yet revenue no customer, program, patent or revenue exists; each step is released by its own gate

03What it can own

The molecule cannot be owned. The method, the data and the ingredient built around it can.

Open a layer to see how it could be protected.

  1. 0The moleculeCurcumin, quercetin or berberine as found in nature

    Not protectable: a naturally occurring compound is not patent-eligible merely because it has been isolated (Myriad, 2013)

  2. 1Process and formulationThe extraction, purification and delivery form

    Patentable if new and non-obvious; patents may not issue

  3. 2Specification, methods and supplier filesWhat is measured on every lot, how, and against which limits

    Trade secrets and contracts

  4. 3Paired lot recordsAuthenticated lots linked to measured extraction, formulation, stability and process data

    Accumulates with every program the contract allows; client data stay with the client

  5. 4Models trained on those recordsPhysics-based and learned models that propose a solvent, a carrier or a process window before material is bought

    Released only after their error is measured on data they never saw

1,132,805

entries from 29 open sources in the THEOBROMA aggregate, 79.12% under open-use licenses. A model built only on open data can be rebuilt by anyone.

Hard to rebuild

Authenticated lots paired with measured extraction, formulation, stability and process data, and the physics that connects them, owned by EUTECNIQ where contracts allow.

No data exclusivity

Supplements receive none of the regulatory data exclusivity approved drugs receive (21 CFR 314.108), so processes, trade secrets and contracts must do that work.

Proposed EUTECNIQ owns no method, patent, dataset or trained model today. Integration alone would not set it apart; the case rests on paid work that leaves a method the company may keep, measured at the day-365 checkpoint. The accumulating moat · Scientific Intelligence

04Why now

Enforcement, guidance and computation are moving at the same time.

  1. FY2022 → FY2025

    22 → 66

    22FY2215FY2339FY2466FY25

    Citations of the dietary-ingredient identity test. A manufacturer may rely on a supplier’s certificate only after confirming its results (21 CFR 111.75(a)(2)(ii)), so every new source creates confirmation work.

    FDA Inspection Observations

  2. October 19, 2026

    NDI guidance final

    FDA finalized its guidance on the identity and safety information for new dietary ingredient notifications; for a nanoscale form, data on the conventional form alone are unlikely to address its safety.

    91 FR 66336

  3. 2025

    Formulations under review

    The UK Committee on Toxicity opened the question of formulations designed to raise curcuminoid bioavailability. A form would need its own exposure and safety data to answer it.

    UK COT TOX/2025/09

  4. Done here, on published data

    Molecule → design space

    Density-functional surfaces of three bioactives fed a solubility model checked against 396 measured mixture solubilities, which capped an extraction model mapped as a design space, before any material was bought.

    The workstation

05How it works

One path from plant to specified ingredient, with a recorded decision at every step.

Schematic, The disciplines the path draws on: Molecular modeling Conformers and force fields Extraction and process design Recovery and mass transfer Advanced delivery Formulation and dispersion Exposure modeling Mechanistic PK and PBPK Robust optimization QbD, uncertainty and design space Five scientific disciplines, one path from plant to specified ingredient.
Schematic Drawn by EUTECNIQ from the text of this page. Icons are schematic and not to scale.

The Ingredient Engine: intake screen (0) and eight core stages (1–8)

0Intake1Discover2Source3Extract4Specify5Deliver6Safety7Scale8Market
  • Inner tracks: a result from that compound’s case study at that stage
  • Curcumin
  • Quercetin
  • Berberine

Schematic Select a stage. A proposed system: no laboratory, plant or model is operating.

Four phases, each with its own question

Select a sector of the wheel, or a phase below, to see what a stage decides, how it works and what the case studies found there.

Decide · stage 0

Intake and feasibility screen

Is there a lawful route for the intended use, and can its evidence be produced at a cost the product can carry?

Proceeds when
A lawful route exists for the intended use, and its evidence can be produced at an acceptable cost.
Produces
A dated screen record that every later gate reads and amends

What is screened

  • Regulatory. The category implied by the intended use and claims; whether the ingredient is a new dietary ingredient, which needs a notification at least 75 days before marketing unless the food-supply exception applies; conservation, import and access rules; the drug path where a therapeutic signal exists.
  • Economic. The cost of the evidence the route needs, the process cost drivers and the margin the market would support.

What the three case studies found here

  • Curcumin

    Screened per program; not part of the computational case study.

  • Quercetin

    Screened per program; not part of the computational case study.

  • Berberine

    Screened per program; not part of the computational case study.

Proposed capability Stage 0 in full · Regulatory overview · NDI notifications · Legal status and counsel · The four named gates

Decide · stage 1

Discover and prioritize

Which candidates deserve laboratory time, and on what evidence?

Proceeds when
The candidate has documented starting evidence, a category hypothesis and a source that can be qualified.
Produces
Candidate dossier, active-constituent map, draft target product profile

Technologies evaluated

  • Literature, database and traditional-use review; traditional use is one possible starting evidence and is not clinical proof
  • Computed molecular descriptors checked against published rules, such as Lipinski’s rule of five
  • Bioactivity-guided fractionation, with dereplication to drop known compounds early
  • LC-HRMS and molecular networking of MS/MS spectra (GNPS)

What the three case studies found here

  • Curcumin +1 more

    32.7 kJ/mol

    The diketo tautomer lies this far above the keto–enol form in the conductor (C-PCM electronic energies, not free energies); three keto–enol conformers lie within 0.4 kJ/mol.

    Computed Workstation

  • Quercetin +1 more

    5.81–8.45

    Seven published first pKa values place the neutral fraction at pH 6.8 between about 0.09 and 0.98.

    Literature-derived FIG 007

  • Berberine

    Cation

    A permanently charged quaternary alkaloid. Explicit-water simulations resolve the water shell around the iminium nitrogen and the four ether oxygens (two methoxy, two methylenedioxy), and track the distance to the chloride counter-ion.

    Computed FIG 008

Proposed capability Stage 1 in full · Discovery and characterization · How a model would be judged · Scientific Intelligence program · Computational research on curcumin, quercetin and berberine

Make the material · stage 2

Authenticate and qualify the source

Is the material what the supplier says it is, and can it be supplied consistently and lawfully?

Proceeds when
Two orthogonal methods agree with an authenticated reference, adulterant screens are negative, and several documented lots are available.
Produces
Identity passport, supplier qualification file, import file
Re-screen
A new species, plant part, origin or supplier

Technologies evaluated

  • Macroscopy and microscopy of crude material
  • HPTLC fingerprint against authenticated reference material (USP ⟨203⟩; see also ⟨563⟩)
  • HPLC or LC-MS marker profile, and targeted tests for known adulterants
  • DNA barcoding of crude material, through partners

and 2 more on the stage page

What the three case studies found here

  • Curcumin

    20.0%

    of 2,235 turmeric samples were adulterated, in a 2026 scoping review of published surveys (Gafner et al.); a content assay cannot tell natural from synthetic curcumin, an isotope ratio can (Perini et al. 2023).

    Published evidence Demonstration 4

  • Quercetin

    No sourcing study yet.

  • Berberine

    No sourcing study yet.

Proposed capability Stage 2 in full · Fingerprint and isotope data · Analytical characterization · Traceable supply chain · Global ingredients

Make the material · stage 3

Extract, separate and optimize

Which process gets the actives out at a defined composition, with an acceptable residue and cost?

Proceeds when
The process gives the target composition repeatably at laboratory scale, the mass balance closes and the residue fits the category.
Produces
Process description, laboratory design space, closed mass balance
Re-screen
A new solvent, concentration or purification step

Technologies evaluated

  • Maceration and percolation; ultrasound- and microwave-assisted extraction; pressurized liquids
  • Supercritical CO₂, with or without a co-solvent; subcritical water
  • Purification by adsorbent resins, membranes, liquid–liquid partition, preparative and countercurrent chromatography, and molecular distillation

What the three case studies found here

  • Curcumin +3 more

    > 10⁷

    Measured mole-fraction solubility across 15 solvents spans more than seven orders of magnitude, water included; a Hansen sphere ranks the organic solvents to about 0.6 log units.

    Computed FIG 012 FIG 013

  • Quercetin +1 more

    1.16 log

    COSMO-SAC error with measured melting data and nothing fitted. Quercetin melts while decomposing, so its fusion data are themselves uncertain.

    Computed Workstation

  • Berberine

    Not covered yet: the berberine salt’s solubility is an electrolyte problem.

Model family

Solvent and thermodynamic intelligence

Proposed capability Stage 3 in full · Extraction and purification · Purification and standardization · Process engineering · Extraction

Make the material · stage 4

Characterize and standardize

What is in the material, how much does it vary, and can every specification be measured reliably?

Proceeds when
Every attribute has a fit-for-purpose method, composition falls in a range that can be justified, and contaminants are below the proposed limits.
Produces
Specification with reasons for each limit, validated methods, certificate-of-analysis format

Technologies evaluated

  • UHPLC with diode-array detection; LC-MS/MS; high-resolution LC-MS for non-targeted screening
  • HPTLC and chromatographic fingerprints compared by chemometrics (statistics that compare whole profiles)
  • GC-MS; ICP-MS for elements; compendial microbiology; NMR through partners

What the three case studies found here

  • Curcumin +1 more

    ≈ 5×

    Two laboratories’ water solubilities of curcumin disagree about fivefold; alcohol data agree within a few percent.

    Measured FIG 014

  • Quercetin

    ≈ 10,000×

    Two published water solubilities differ nearly 10,000-fold; an independent 37 °C value falls between them.

    Measured FIG 014 FIG 028

  • Berberine

    No specification study yet.

Proposed capability Stage 4 in full · Analytical characterization · Method development · Purification and standardization · Targeted and non-targeted analysis

Make it work · stage 5

Engineer delivery

Which barrier limits the active, and which carrier addresses it in the intended format?

Proceeds when
The prototype meets its physical and chemical stability targets, and a stated mechanism links the carrier to the identified barrier.
Produces
Formulation prototype, delivery technology dossier
Re-screen
A new carrier, particle size or dosage form

Technologies evaluated

  • Lipid-based and self-emulsifying systems, classed with the lipid formulation classification system
  • Nanoemulsions; phospholipid complexes; cyclodextrin inclusion complexes
  • Amorphous solid dispersions; encapsulation; spray drying and freeze-drying to stable powders

What the three case studies found here

  • Curcumin

    10²–10⁵×

    At studied doses, curcumin needs hundreds to hundreds of thousands of times the ICH M9 volume to dissolve.

    Computed FIG 028

  • Quercetin

    4×

    A rat study reports a fourfold AUC gain for a solid dispersion; a nine-run design does not separate its two factors statistically.

    Computed FIG 024 FIG 029

  • Berberine +2 more

    17×

    Berberine hydrochloride is 17 times more soluble at pH 6.8 than at pH 1.2, and more soluble in that buffer than in any oil or surfactant tested.

    Literature-derived FIG 022

Proposed capability Stage 5 in full · Advanced delivery · Emulsions and colloids · Drying and particle engineering · Bioavailability by design

Make it work · stage 6

Establish safety and performance evidence

Is the ingredient safe at the intended intake, and does the product do what its design is meant to do?

Proceeds when
No hazard is known at the intended exposure, EDI/ADI is 1 or less, and the performance target set at stage 5 is met by the kind of evidence the intended claim needs.
Produces
Safety and exposure assessment, study reports, stability data
Re-screen
A new population, dose or claim

Technologies evaluated

  • Exposure estimate from the intended use; history-of-use and literature review
  • In vitro screens; studies to OECD guidelines at GLP partner laboratories (21 CFR Part 58)
  • NOAEL or benchmark dose; the threshold of toxicological concern for minor constituents
  • Enzyme and transporter interaction screens

and 2 more on the stage page

What the three case studies found here

  • Curcumin

    0.28%

    Unconjugated curcumin is about 0.28% of total curcumin exposure (90% interval 0.11–0.66%). Claims built on total curcumin describe the conjugates.

    Calibrated FIG 033

  • Quercetin

    ≈ 25×

    A Bayesian calibration of the 4′-glucoside and rutin arms recovers absorption rates that differ about 25-fold and an elimination half-life of 10.7 h, with four chains converged.

    Calibrated FIG 041 FIG 042

  • Berberine +2 more

    1.6× · 3.4×

    Two animal studies report these exposure gains, from reference arms whose peak concentrations per mg/kg are about 70 and 16,000 times those of the human study.

    Computed FIG 029

Model family

Mechanistic biological modeling

Proposed capability Stage 6 in full · Toxicology and exposure · NDI notifications · Clinical research · Translational research

Scale and deliver value · stage 7

Scale, validate and transfer

Does a larger process make on-specification material with its critical parameters known, and can another site repeat it?

Proceeds when
Consecutive pilot batches meet the specification under a written control strategy, and every release attribute has a validated method.
Produces
Process development and transfer package, control strategy
Re-screen
A change of process, scale or site

Technologies evaluated

  • Pilot extraction, evaporation, solvent recovery and pilot drying
  • Mass and energy balances; designed experiments; dimensionless scale-up rules
  • Quality by design: critical quality attributes (CQAs) linked to critical process parameters (CPPs), with risk ranking
  • Process analytical technology, such as near-infrared monitoring of an extraction

and 1 more on the stage page

What the three case studies found here

  • Curcumin

    No scale-up study yet.

  • Quercetin

    No scale-up study yet.

  • Berberine

    No scale-up study yet.

Proposed capability Stage 7 in full · Technology transfer · Process engineering · QbD and control strategy · Quality system

Scale and deliver value · stage 8

Commercialize, license, supply or partner

Which route turns the evidence into value: a client program, a license, supply or a partnered drug program?

Proceeds when
A customer or partner commits, ownership and data terms are agreed before work starts, and counsel has reviewed freedom to operate.
Produces
IP and commercialization assessment, supply and quality agreements, or a partnering file
Re-screen
New claims, a new market or a drug use

Tools evaluated

  • Prior-art and patent landscaping; ownership mapping under written agreements
  • Freedom-to-operate review by patent counsel
  • A commercial model and a supply plan
  • Market-access assessment by category and country

What the three case studies found here

  • Curcumin

    No commercial route chosen.

  • Quercetin

    No commercial route chosen.

  • Berberine

    No commercial route chosen.

Proposed capability Stage 8 in full · Scientific deliverables · Services · Legal status and counsel · Supplement or drug

The same system as flow charts:

Computation proposes before material is bought; material moves through Engine stages 2 to 8, and measured lot data flow back to the models.

Molecule to manufacturing, as one system

COMPUTATION · proposes before material is boughtScientific Intelligencetrained on paired lot recordsMolecular thermodynamicssolvent and partner screeningpredictions with intervalsmeasured lot dataMATERIAL · Ingredient Engine stages 2 to 82Sourceidentity and supplierRecord: identity passport,supplier file3Extractionyield and selectivityRecord: processdescription, mass balance4Standardizationfingerprint and limitsRecord: specification,validated methods5Deliverydispersion in the gutRecord: prototype,delivery dossier6Exposure and safetywhat reaches the bloodRecord: safety andexposure assessment7Scale-uptransfer to the plantRecord: transfer package,control strategy8Specified ingredient, supplied or licenseda specification, methods and exposure data a buyer can verifyCOMPUTATIONScientific Intelligencetrained on paired lot recordsMolecular thermodynamicssolvent and partner screeningpredictionslot dataMATERIAL · stages 2 to 82Sourceidentity and supplier3Extractionyield and selectivity4Standardizationfingerprint and limits5Deliverydispersion in the gut6Exposure and safetywhat reaches the blood7Scale-uptransfer to the plant8Specified ingredienta specification, methods andexposure data a buyer can verify;supplied or licensed
  • Material path
  • Recorded decision: progress, repeat or stop
  • Predictions
  • Measured data
Schematic A proposed system: no laboratory, plant or model is operating. Stage names and records are those of the Ingredient Engine; the equations behind each science are there too. Select a station to open its page.

Eight stages take a candidate from first screen to a commercial outcome. Lawful route and economics are screened at intake and again whenever material, process, formulation or intended use changes, so a program can stop before its next, costlier step.

Regulatory and economic feasibility screen0Intake1Discover2Source3Extract4Specify5Deliver6Safety7Scale8Marketabcde
  1. Stage 3 back to 2: requalify source
  2. Stage 4 back to 3: re-optimize
  3. Stage 6 back to 5: reformulate
  4. Stage 7 back to 3: drift at scale: redesign process
  5. Stage 8 back to 6: claim needs more evidence
  1. 0Intake and feasibility screenScreen record
  2. 1Discover and prioritizeCandidate dossier, draft target profile
  3. 2Authenticate and qualify the sourceIdentity passport, supplier file; re-screen if the material changes
  4. 3Extract, separate and optimizeProcess description, mass balance; re-screen if the process changes
  5. 4Characterize and standardizeSpecification, validated methods
  6. 5Engineer deliveryPrototype, delivery dossier; re-screen if the formulation changes
  7. 6Establish safety and performance evidenceSafety and exposure assessment; re-screen if the intended use changes
  8. 7Scale, validate and transferTransfer package, control strategy; re-screen if the process changes
  9. 8Commercialize, license, supply or partnerClient program, license, supply or partnered drug program; re-screen if the intended use changes
Educational schematic Diamonds are gates where a program proceeds, repeats or stops. Dashed drops mark the stages whose changes send it back to the feasibility screen. From stage 8 a program can go four ways: develop for a client, license a process, supply an ingredient or partner a drug candidate.

One chain of models, from molecule to robust design.

Each stage passes defined quantities to the next, so a molecular or formulation decision can be traced to its effect on extraction, exposure and process robustness. Select a method to open the figure behind it.

EUTECNIQ · proposed multiscale development engine

  1. Molecular identity and mechanics

  2. Tautomer, charge state, conformer ensemble and descriptors
  3. Solvent and thermodynamic intelligence

  4. Solubility by solvent and excipient, residual-solvent class, recovery energy
  5. Delivery-system design

  6. Dose form, drug loading, droplet size, release in each medium
  7. Mechanistic biological modeling

  8. Exposure of the parent compound and its metabolites, with uncertainty
  9. Bayesian optimization and robust QbD

Experimental results would feed back into every model. None has been measured yet.

  • calculated here
  • published data reanalyzed
  • shown on illustrative inputs
  • proposed
  • planned

Scientific Intelligence: the six proposed model families and their gates

Workstation

Three bioactives, from computed molecular surfaces to an extraction design space

Density-functional surfaces of curcumin, quercetin and berberine feed a solubility model that is checked against 396 measured mixture solubilities; that solubility caps an extraction model, and the result is mapped as an extraction design space. Links without a model are shown as gaps.

Open the workstation

Electrostatic potential of curcumin on its electron-density surface
calculated here Curcumin, electrostatic potential (BP86/def2-TZVP)
Solubility landscape and extraction design space for curcumin
illustrative kinetic inputs Solubility landscape and extraction design space

06Proof of concept · computational research on published data

Three compounds, three hard questions, answered as far as published data allow.

Three difficult bioactives, worked on published data before a laboratory exists, to test the method rather than to sell these compounds: a poorly soluble, unstable molecule (curcumin), a molecule whose basic data conflict (quercetin) and a permanently charged one that crosses membranes poorly (berberine).

Sixty figures on curcumin, quercetin and berberine, each with its data, its code and a label for the kind of evidence it is. Choose a compound to see one result in full.

Computed on published data Scenario kinetics One result, one decision

Which water–ethanol mixtures can pull curcumin out of turmeric in an hour? Two connected models give a different answer from either alone.

The problem

Curcumin dissolves in water only at nanogram-to-microgram per milliliter levels, so an extraction model that ignores solubility can promise recoveries the solvent cannot hold.

Data used

170 measured solubilities in 15 pure solvents; 396 measured solubilities in alcohol–water mixtures (Shen et al. 2019, via NIST ThermoML), none used in the fit; curcumin content of the rhizome, 3.14% w/w (Tayyem et al. 2006).

What was calculated

Density-functional surfaces of the molecule → solubility by COSMO-SAC with one fitted parameter → a diffusion model of extraction capped by that solubility → Monte Carlo over the uncertain inputs. 0.25 mm particles, 8 kg solvent per kg, 60 minutes.

Alternatives compared

Diffusion alone against diffusion with the solubility limit; three keto–enol conformers and the diketo tautomer; a semi-empirical against a density-functional geometry.

Finding

In the model, diffusion alone gives at least a 90% chance of recovering 80% of the curcumin on 100% of the 5–45 °C, 30–100% ethanol grid; with the solubility limit, 34%, a model-dependent scenario rather than a measured operating window. At 45 °C the boundary sits at 40% ethanol. Conformer choice moves predictions by at most 0.01 log units, the geometry by 0.04.

Limitation

The kinetic inputs are scenarios, and the solubility model is up to 100-fold low at 10–40% cosolvent, so the boundary is a hypothesis to test, not a process setting.

Next experiment

Measure curcumin solubility in the actual extraction solvent at the chosen ethanol fraction and temperature (shake-flask, HPLC); measure extraction kinetics on milled rhizome of the specified particle size to replace the scenario diffusivity.

Why it matters commercially

Solvent choice sets the residual-solvent class, the energy to recover solvent and the cost per kilogram; solvent recovery usually sizes the plant. A computed window tells the first extraction runs where to look. No saving in cost or time is claimed until those runs are done.

Curcumin solubility landscape over ethanol fraction and temperature, and the probability of missing 80% recovery with and without the solubility limit
Illustrative kinetic inputs a, predicted solubility with the measured points; b, with the solubility limit; c, diffusion alone. The workstation and its methods

Curcumin: from tautomer to plasma

Curcumin dissolves readily in DMSO and acetone but in water only at nanogram-to-microgram per milliliter levels, degrades within minutes to hours at neutral pH, and circulates in people mostly as conjugates. Each of those facts is a design constraint.

  1. 0Intake
  2. 7Scale
  3. 8Market
  • Stage 1 · Discover

    32.7 kJ/mol

    The diketo tautomer lies this far above the keto–enol form in the conductor (C-PCM electronic energies, not free energies); three keto–enol conformers lie within 0.4 kJ/mol.

    Computed Workstation

  • Stage 1 · Discover

    0.49 kcal/mol

    A 100-start conformer search misses the lowest diketo minimum by this much: two tautomers must be modeled, and the diketo form needs a far larger search.

    Computed FIG 004 FIG 007

  • Stage 2 · Source

    20.0%

    of 2,235 turmeric samples were adulterated, in a 2026 scoping review of published surveys (Gafner et al.); a content assay cannot tell natural from synthetic curcumin, an isotope ratio can (Perini et al. 2023).

    Published evidence Demonstration 4

  • Stage 3 · Extract

    > 10⁷

    Measured mole-fraction solubility across 15 solvents spans more than seven orders of magnitude, water included; a Hansen sphere ranks the organic solvents to about 0.6 log units.

    Computed FIG 012 FIG 013

  • Stage 3 · Extract

    0.70 log

    COSMO-SAC error over 170 pure-solvent points from DFT surfaces, with one fitted parameter (enthalpy of fusion, 46.8 kJ/mol); 1.19 on 396 aqueous mixtures not used in the fit.

    Calibrated Workstation

  • Stage 3 · Extract

    34%

    of the 5–45 °C, 30–100% ethanol grid gives at least a 90% chance of recovering 80% of the curcumin once the predicted solubility limit is applied, against 100% for diffusion alone. The kinetic inputs are scenarios.

    Illustrative Workstation

  • Stage 3 · Extract

    Acetone

    needs the least latent heat per kilogram dissolved among low-boiling ICH Q3C Class 3 solvents; THF (Class 2) and DMSO (Class 3, boiling near 190 °C) need the least overall.

    Computed FIG 015

  • Stage 4 · Specify

    ≈ 5×

    Two laboratories’ water solubilities of curcumin disagree about fivefold; alcohol data agree within a few percent.

    Measured FIG 014

  • Stage 4 · Specify

    ≈ 1.3 h

    to a 10% loss at 25 °C in protein-containing broth, from refitted Arrhenius kinetics; published half-lives near pH 7 run from minutes to hours.

    Computed FIG 049 FIG 026

  • Stage 5 · Deliver

    10²–10⁵×

    At studied doses, curcumin needs hundreds to hundreds of thousands of times the ICH M9 volume to dissolve.

    Computed FIG 028

  • Stage 6 · Safety

    0.28%

    Unconjugated curcumin is about 0.28% of total curcumin exposure (90% interval 0.11–0.66%). Claims built on total curcumin describe the conjugates.

    Calibrated FIG 033

Stages without a result yet
  • 0 Screened per program; not part of the computational case study.
  • 7 No scale-up study yet.
  • 8 No commercial route chosen.

Proposed What EUTECNIQ would measure next

  1. 1Measure the fusion enthalpy and aqueous solubility of the crystal form used.
  2. 2Measure degradation kinetics in the intended product matrix at three temperatures, with LC-MS product identification.
  3. 3Run a crossover study of a candidate ingredient that reports parent curcumin and its conjugates separately.

Why it matters. For an ingredient developer, the numbers that matter are the parent compound that reaches plasma and the fraction that survives manufacture and storage. Designing to those quantities, rather than to total curcumin, separates a defensible product from one whose claim rests on conjugates.

The results support

  • Choosing extraction solvents on measured solubility, recovery energy and residual-solvent class together.
  • Requiring matrix-specific degradation kinetics before any stability claim.
  • Reporting unconjugated and total curcumin separately in any exposure study.

They do not support

  • A recommended solvent, process or shelf life for a product.
  • Any statement that a formulation increases bioavailability of unconjugated curcumin, beyond the one study analyzed.

Featured result

FIG 033, Curcumin: Unconjugated curcumin is about 0.28% of total curcumin exposure (90% interval 0.11–0.66%). Claims built on total curcumin describe the conjugates.
Calibrated FIG 033. Full size, data and sources

Curcumin

How much unconjugated curcumin reaches the blood?

  • FIG 004 Conformer search: 100 starts miss the lowest diketo minimum by 0.49 kcal/mol
  • FIG 026 Reported half-lives near pH 7 run from minutes to hours

The curcumin case study

Method
Two one-compartment models calibrated with Markov chain Monte Carlo (PyMC, NUTS) to the published medians and ranges of one human arm (micellar curcumin, 576 mg, n = 9).
Finding
Unconjugated curcumin is about 0.28% of total curcumin exposure (90% interval 0.11–0.66%). Claims built on total curcumin describe the conjugates.
Limits
One study arm of nine people, summary statistics only; the spread of each median was inferred from its range.
Next experiment
A crossover study of a candidate ingredient that reports parent curcumin and its conjugates separately.

Quercetin: resolving conflicting data before modeling

For quercetin, the limiting factor is not the models but the data: its first pKa and its water solubility are each reported over a range wide enough to change any conclusion drawn from them.

  1. 0Intake
  2. 2Source
  3. 7Scale
  4. 8Market
  • Stage 1 · Discover

    5.81–8.45

    Seven published first pKa values place the neutral fraction at pH 6.8 between about 0.09 and 0.98.

    Literature-derived FIG 007

  • Stage 1 · Discover

    6 sites

    Explicit-water simulations of the neutral aglycone resolve the water shell around each of its five hydroxyl groups and its carbonyl.

    Computed FIG 008 FIG 009

  • Stage 3 · Extract

    1.16 log

    COSMO-SAC error with measured melting data and nothing fitted. Quercetin melts while decomposing, so its fusion data are themselves uncertain.

    Computed Workstation

  • Stage 3 · Extract

    Weak

    The published group-contribution Hansen center orders the organic solvents only weakly and cannot be tested in water.

    Computed FIG 012

  • Stage 4 · Specify

    ≈ 10,000×

    Two published water solubilities differ nearly 10,000-fold; an independent 37 °C value falls between them.

    Measured FIG 014 FIG 028

  • Stage 5 · Deliver

    4×

    A rat study reports a fourfold AUC gain for a solid dispersion; a nine-run design does not separate its two factors statistically.

    Computed FIG 024 FIG 029

  • Stage 6 · Safety

    ≈ 25×

    A Bayesian calibration of the 4′-glucoside and rutin arms recovers absorption rates that differ about 25-fold and an elimination half-life of 10.7 h, with four chains converged.

    Calibrated FIG 041 FIG 042

Stages without a result yet
  • 0 Screened per program; not part of the computational case study.
  • 2 No sourcing study yet.
  • 7 No scale-up study yet.
  • 8 No commercial route chosen.

Proposed What EUTECNIQ would measure next

  1. 1Measure solubility at 25 and 37 °C on three lots, with the solid form checked by X-ray powder diffraction before and after.
  2. 2Measure the pKa potentiometrically in a co-solvent series.
  3. 3Calibrate dissolution models against the measured values.

Why it matters. A formulation built on a solubility value that is wrong by orders of magnitude is likely to fail in scale-up or in the clinic. Settling these two numbers is inexpensive compared with the development work that depends on them.

The results support

  • Remeasuring quercetin’s water solubility and first pKa under controlled conditions before modeling.
  • Treating glycoside form as a primary design variable for absorption rate.

They do not support

  • Choosing either published water solubility for formulation design.
  • Any human bioavailability claim for an aglycone formulation.

Featured result

FIG 014, Quercetin: Two laboratories' water solubilities of quercetin differ about 10,000-fold, while two laboratories' curcumin data in ethanol and isopropanol agree within a few percent.
Measured FIG 014. Full size, data and sources

Quercetin

How soluble is quercetin in water?

  • FIG 007 Seven published pKa values put the neutral fraction at pH 6.8 between 0.09 and 0.98
  • FIG 024 A nine-run formulation design shows no factor significant at 5%

The quercetin case study

Method
Published mole-fraction solubilities (BigSolDB 2.0) fitted source by source with van 't Hoff equations and compared at 25 °C, with an independent 37 °C measurement as a check.
Finding
Two laboratories' water solubilities of quercetin differ about 10,000-fold, while two laboratories' curcumin data in ethanol and isopropanol agree within a few percent.
Limits
The sources' solid forms, equilibration times and analytical finishes were not re-examined; neither value is excluded.
Next experiment
Shake-flask solubility at 25 and 37 °C on three lots, with the solid form checked by X-ray powder diffraction before and after.

Berberine: a cation with a permeability problem

Berberine dissolves reasonably well at intestinal pH but crosses membranes poorly and varies widely between people. Lipid systems help in animals; human formulation data are still missing.

  1. 0Intake
  2. 2Source
  3. 3Extract
  4. 4Specify
  5. 7Scale
  6. 8Market
  • Stage 1 · Discover

    Cation

    A permanently charged quaternary alkaloid. Explicit-water simulations resolve the water shell around the iminium nitrogen and the four ether oxygens (two methoxy, two methylenedioxy), and track the distance to the chloride counter-ion.

    Computed FIG 008

  • Stage 5 · Deliver

    17×

    Berberine hydrochloride is 17 times more soluble at pH 6.8 than at pH 1.2, and more soluble in that buffer than in any oil or surfactant tested.

    Literature-derived FIG 022

  • Stage 5 · Deliver

    20 mg/g

    Only combinations with Kolliphor RH 40 formed nanoemulsions in a 46-combination screen; loading tops out at 20 mg/g before the system crystallizes.

    Literature-derived FIG 021 FIG 023

  • Stage 5 · Deliver

    12 runs

    A D-optimal mixture design around the published composition, and a linkage map from product targets to inputs, set out the next experiments.

    Planned FIG 027 FIG 051

  • Stage 6 · Safety

    1.6× · 3.4×

    Two animal studies report these exposure gains, from reference arms whose peak concentrations per mg/kg are about 70 and 16,000 times those of the human study.

    Computed FIG 029

  • Stage 6 · Safety

    16×

    The middle 90% of 4,000 simulated subjects spans a 16-fold range of AUC, and the summary data cannot tell fast absorption from slow absorption.

    Predicted FIG 048 FIG 038

  • Stage 6 · Safety

    Elimination

    Elimination and apparent volume dominate AUC; absorption rate dominates Tmax, so faster-releasing formulations sharpen the peak without much change in AUC.

    Computed FIG 039 FIG 040

Stages without a result yet
  • 0 Screened per program; not part of the computational case study.
  • 2 No sourcing study yet.
  • 3 Not covered yet: the berberine salt’s solubility is an electrolyte problem.
  • 4 No specification study yet.
  • 7 No scale-up study yet.
  • 8 No commercial route chosen.

Proposed What EUTECNIQ would measure next

  1. 1Run the D-optimal mixture design for droplet size, emulsification time and loading.
  2. 2Run a human crossover study against a reference product, measuring berberine and its main metabolites.

Why it matters. Because AUC in people is set mainly by elimination and volume, a formulation can change the shape of the curve more easily than the total exposure. Knowing that before a clinical study is the difference between a realistic and an unrealistic target.

The results support

  • Mapping the SMEDDS composition space with a designed experiment instead of one-factor screens.
  • Sizing any berberine study for wide between-subject variability.
  • Measuring metabolites or using intravenous data to identify absorption kinetics.

They do not support

  • A human bioavailability claim for any berberine formulation.
  • Transferring animal fold changes to people.

Featured result

FIG 048, Berberine: The middle 90% of simulated subjects spans a 16-fold range of AUC, and the published data cannot tell fast absorption with slow elimination from the reverse.
Predicted FIG 048. Full size, data and sources

Berberine

How variable is berberine exposure from one 300 mg dose?

  • FIG 038 Fast and slow absorption fit the summary data equally well
  • FIG 021 Only Kolliphor RH 40 combinations formed nanoemulsions in a published screen

The berberine case study

Method
A typical-subject model calibrated to the published summary data (n = 12), combined with between-subject variability matched to the reported coefficients of variation: 4,000 simulated subjects.
Finding
The middle 90% of simulated subjects spans a 16-fold range of AUC, and the published data cannot tell fast absorption with slow elimination from the reverse.
Limits
Variability is inferred from summary coefficients of variation, with no covariates and no individual concentration data.
Next experiment
A human crossover study against a reference product that measures berberine and its main metabolites.

The 60 figures by kind of evidence

21
Completed computational analyses force-field, statistical and flow calculations, including one benchmark
7
Published measurements reanalyzed compiled, converted or re-plotted, without a fitted model
15
Literature-calibrated models 10 calibrated to published human data and 5 predictions made with them
15
Illustrative simulations methods shown on a simulator or simulated data with stated inputs
2
Planned experiments designed, not yet run
0
Trained proprietary models or laboratory results the learned models remain proposed

The problem, measured

The same name on the label can hide a 5.8-fold difference in one constituent.

Rutin, one flavonol glycoside, measured in 51 batches of ginkgo tablets and capsules from 25 manufacturers. Add the rules of an example specification one at a time and see how many batches it would release.

00.511.522.53Rutin, mg per 40 mg extract0.50 to 2.91: a 5.8-fold range
00.511.522.53Rutin, mg per 40 mg extract0.50 to 2.91: a 5.8-fold range
  • Released
  • Held for supplier history
  • Outside the example specification
Published evidence Liu et al., Chin Med 2022;17:72, Table 2. One dot per batch.
Add the example release rules one at a time

51 batches, no rule applied.

Hypothetical example The rules are the example specification of Demonstration 3, not a monograph or a legal limit. A batch outside it is outside that example. That is not a finding that any product was unsafe, adulterated or unlawful.

Change the limits and the tests in Demonstration 3

Demonstration 4 · one program

Five decisions on one turmeric extract, all based on published evidence.

Schematic, Five decisions on one turmeric extract: Source Turmeric rhizome Authenticate Natural or synthetic? Extract Four solvents, one rhizome Specify Draft specification Deliver Exposure, not dose Each decision rests on published evidence; the plate below gives the values and their sources.
Schematic The five decisions on the plate below, drawn by EUTECNIQ. Icons are schematic; the plate carries the cited values.
  1. ISourceStage 2

    Turmeric rhizome

    Content reported for the dry rhizome, by source and measure

    Curcuminoids2–9%Coloring principles3–5%Curcumin0.6–5%0%5%10%

    Published Priyadarsini 2014; JECFA 2004; EMA 2018

  2. IIAuthenticateStage 2

    Natural or synthetic?

    27 samples; the content assay cannot see what the isotope ratio can

    Curcuminoid content, HPLCCannot tell them apartHydrogen isotope ratio21 natural6 synthetic

    Published Perini et al. 2023

  3. IIIExtractStage 3

    Four solvents, one rhizome

    Acetone: the richest oleoresin, recovery within error of the highest

    253035202428Curcuminoids in oleoresin, %Yield, %EthanolMethanolCO₂ + ethanolAcetone

    Measured Barriga-Sánchez et al. 2024

  4. IVSpecifyStage 4

    Draft specification

    Each line exists because an earlier stage put it there

    • Curcumin, demethoxy- and bisdemethoxycurcuminReported each and total
    • Natural originNatural reference range
    • Lead≤ 2 mg/kg
    • Residual acetone≤ 30 mg/kg

    Proposed Limits adopted from JECFA 2003 and 21 CFR 173.210

  5. VDeliverStage 5

    Exposure, not dose

    Times a standard extract’s plasma exposure of total curcuminoids, one study, 12 adults (curcumin alone: 85× for the γ-cyclodextrin form)

    Standard extract1×Turmeric oil form1.1×Phytosome8.5×γ-Cyclodextrin39.1×

    Published Purpura et al. 2018

Hypothetical program The program is an example; every value is from the cited study or specification. Change the decisions and see which stages reopen

The Ingredient Engine

One development system leads to several commercial outcomes.

8
Engine stages, each ending in a documented decision to proceed, repeat or stop
6
Proposed model families, each released only by a measured test
1
First paid service. U.S. supplement makers must verify the identity of every dietary ingredient (21 CFR 111.75); in a 2026 scoping review of published surveys, 20.0% of 2,235 turmeric samples were adulterated (Gafner et al.)
0
Laboratories operating, models trained or samples measured today; funding follows measured gates

The eight stages, their gates and repeat loops are drawn under How it works: decisions and loops. From stage 8 a program can go four ways:

  • Develop for a client
  • License a process
  • Supply an ingredient
  • Partner a drug candidate

Four demonstrations, worked on published data

The Ingredient Engine, stage by stage

07Business model · path to value

From one paid problem to ingredients the company owns.

Each step depends on evidence from the one before it; none follows automatically. Laboratory spending would begin only after 90 days, and only if clients have paid deposits and the work shows a measured margin.

Proposed flagship case · not a program

A turmeric extract with verified natural origin and measured exposure

  • Natural origin verified per lot by hydrogen isotope ratio
  • The three curcuminoids specified by a validated HPLC method (AOAC 2016.16), with proposed limits of 2 mg/kg lead and 30 mg/kg residual acetone
  • A delivery form with its own exposure and safety data
  • Made at first by qualified cGMP contract manufacturers; no plant of its own

$141.8MU.S. mainstream multi-outlet sales of turmeric supplements, 2024 (fourth among herbal supplements)

$37.1MSPINS natural channel, 2024, where turmeric ranked first for the third consecutive year

Smith, Lang and Craft, HerbalGram 2025 (SPINS data; scanned channels exclude direct-to-consumer sales). No program, customer, patent or revenue exists; nothing here is a forecast. The flagship case

Why this would differ from a testing laboratory

What is sold
A result for each sampleA specified ingredient per kilogram, or a license to make it
Revenue repeats when
The client sends the next sampleThe customer reorders under a supply or license agreement
What stays with the company
Little: data and results belong to the clientThe specification, process know-how, the safety and exposure file, and any patent that issues

Fee-for-service testingProposed ingredient owner

  1. FeeA paying problemA fixed-scope package, starting with supplier qualification and comparability (Package B)
  2. FeeContracted revenueAccepted deliverables, invoiced and paid
  3. Know-howRepeatable methodsMethods and decision rules reused on the next program, where contracts allow
  4. Owned assetA proprietary ingredientOnly where ownership is established: work on EUTECNIQ’s own account, or rights assigned in contract
  5. RecurringSupply and licensesPaid per kilogram or per license, without a new statement of work

Each step rests on the one before; heights show order, not amounts.

Proposed capability The value path, the flagship case and the first test

08Founder

A published scientific record and industrial operating experience.

Dr. Amir H. Mehrkesh

Public record, checked October 22, 2026

2015
Ph.D., University of Colorado Denver; dissertation on the optimization-based design of ionic liquids
13
Publications, 2010–2016 (12 journal articles, 1 proceedings chapter), 9 as first author
6
Granted patents in the United States, Japan and Europe from three invention families, as co-inventor; not EUTECNIQ intellectual property

Industrial experience since 2007 Founder-reported

  • Botanical and functional products.

    Built and led a research and quality-control group, and designed, equipped and qualified an in-house laboratory. Human PK/PD studies informed product decisions, and he led technology transfers into manufacturing.

  • Pharmaceutical manufacturing.

    Led engineering and operations teams across a multi-site cGMP network making active pharmaceutical ingredients; managed multi-million-dollar capital and OPEX projects, including cGMP expansions.

  • Advanced materials.

    Took R&D programs from laboratory proof of concept to pilot scale with molecular modeling, design of experiments and machine-learning screening.

  • Industrial extraction and separation.

    Process design, debottlenecking and energy optimization with simulation and techno-economic evaluation.

Results belong to the prior employers, which are not named, and not to EUTECNIQ. He is the company’s only team member today. Publications, patents and the specialists still to recruit

For collaborators

Start with one ingredient or one question. A first message needs no confidential information; a mutual nondisclosure agreement comes before any formula or process detail.

For investors

The proposed phases, uses of capital and milestones, with the founder’s record and the risks.

Information only. Not an offer of securities.

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]